scholarly journals Achievments of control of seasonal allergic rhinitis symptoms: the results of open, randomized comparative study of second generation antihistamines

2017 ◽  
Vol 14 (2) ◽  
pp. 37-46
Author(s):  
O S Bodnya ◽  
N M Nenasheva ◽  
G V Andrenova ◽  
D O Siniavkin ◽  
Y V Bodnya ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Second Generation ◽  
Day Treatment ◽  
Allergic Diseases ◽  
Adult Patients ◽  
Eosinophilic Cationic Protein ◽  
Cationic Protein ◽  
First Choice ◽  
Baseline Values

Seasonal allergic rhinitis (SAR) is one of the most common allergic diseases. The first choice for control of SAR symptoms is the second-generation antihistamines (AHP-II). The aim of this study was to evaluate the comparative efficacy of ebastine 20 mg/day, cetirizine 10 mg/day, and loratadine 10 mg/day in adult patients with mild symptoms of SAR due to pollen grass allergy. 30 patients aged 18 to 65 years who received treatment for 14 days took part in the study. The duration of the study for one patient varied from 25 to 28 days. As a result, the efficiency of all three AHP II in the control of mild symptoms of SAR was demonstrated. However, the analysis of the scales (TNSS and TNNSS) after the end of the 14-day treatment period revealed that compared to patients treated with loratadine and cetirizine (TNSS scale (p=0,0303), TNNSS (p=0,0091) the best results were observed in the group of patients taking ebastine. Moreover, patients who received the ebastine experienced a statistically insignificant but steady tendency to decrease the level of eosinophilic cationic protein (ECP) in nasal flushing (-37,9% of the baseline values), in contrast to loratadine and cetirizine. All drugs showed a high safety profile. To conclude, the investigated AHPs -II are effective and safe in control of mild symptoms of SAR in adult patients, though the rate of onset of the effect and its level for nasal and non nasal symptoms was significantly higher in patients receiving ebastine 20 mg compared to cetirizine 10 mg and loratadine 10 mg.

scholarly journals THE ROLE OF MODERN ANTIHISTAMINES IN THE TREATMENT OF ALLERGIC DISEASES

2017 ◽  
Vol 14 (4-5) ◽  
pp. 80-88
Author(s):  
N M Nenasheva
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Second Generation ◽  
Allergic Diseases ◽  
Pharmaceutical Market ◽  
Common Diseases ◽  
First Choice ◽  
Antihistamine Drug

Allergic rhinitis and urticaria - are common diseases which influence on the quality of life of patients reducing day activity and educability. The second generation of antihistamines are the first choice in the treatment of these diseases. At Russian pharmaceutical market a few dozens of different preparations of this group are available. Most of them are generic forms. The purpose of this article is to show the place of modern antihistamines in allergic rhinitis and urticaria therapy and to find out the best equivalent of generic antihistamine drug in comparison with the original one.

scholarly journals Cetirizine, a Second-Generation H1 Antagonist, Modulates Rantes and MCP-1 Levels in Allergic Rhinitis

2002 ◽  
Vol 15 (2) ◽  
pp. 113-118 ◽  
Author(s):  
G. Bruno ◽  
P. Andreozzi ◽  
U. Graf ◽  
F. Tega ◽  
G. Santangelo ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Second Generation ◽  
Allergic Diseases ◽  
Serum Levels ◽  
Control Group ◽  
Baseline Serum ◽  
Before And After ◽  
Healthy Control ◽  
Baseline Values ◽  
H1 Antagonist

Chemokines and their receptors are involved in several allergic diseases. We measured RANTES and MCP-1 levels in sera of allergic rhinitis patients, and we also evaluated the effect of cetirizine, a second-generation H1 antagonist, on these chemoattractant proteins. 15 subjects were studied (10 males and 5 females; mean age: 26.7 years). They were suffering from perennial or seasonal allergic rhinitis induced by Dermatophagoides pteronyssinus (8 patients) or by grasses (7 patients). RANTES and MCP-1 serum levels were detected with an enzyme immunoassay before and after two weeks of treatment with 10 mg of cetirizine daily, and again after two weeks of washout. Baseline serum levels of RANTES and MCP-1 chemokines were significantly higher (p < 0.02 and p = 0.007, respectively) in allergic patients than in the healthy control group. Cetirizine resulted in a significant decrease in RANTES (p < 0.02) and MCP-1 (p = 0.003) versus baseline values. There is an increase in RANTES and MCP-1 in allergic rhinitis, which is counteracted by cetirizine.

A Comparison of Aqueous Suspensions of Budesonide Nasal Spray (128 μg and 256 μg Once Daily) and Fluticasone Propionate Nasal Spray (200 μg Once Daily) in the Treatment of Adult Patients with Seasonal Allergic Rhinitis

1997 ◽  
Vol 11 (4) ◽  
pp. 323-330 ◽  
Author(s):  
Martin A. Stern ◽  
Ronald Dahl ◽  
Lars P. Nielsen ◽  
Bente Pedersen ◽  
Camilla Schrewelius
Keyword(s):  
Allergic Rhinitis ◽  
Fluticasone Propionate ◽  
Nasal Spray ◽  
Seasonal Allergic Rhinitis ◽  
Adult Patients ◽  
Once Daily ◽  
Treatment Groups ◽  
Runny Nose ◽  
Aqueous Suspensions ◽  
Symptom Scores

The efficacy of aqueous suspensions of budesonide nasal spray and fluticasone propionate nasal spray, in the treatment of seasonal allergic rhinitis, was compared in a large, placebo-controlled, two-center study. A 1-week baseline period was followed by a 4- to 6-week treatment period during which 635 adult patients, aged 18–72 years, were randomized to receive either placebo, budesonide 128 μg, or 256 μg once daily, or fluticasone propionate, 200 μg once daily. Nasal and eye symptoms, overall treatment efficacy and safety assessments were made during the study period. Combined, as well as individual, nasal symptoms were significantly improved in all three active treatment groups compared with placebo therapy. Treatment with 256 μg/day of budesonide was found to be significantly more effective in reducing the sneezing score compared with 200 μg/day of fluticasone propionate. Analysis of symptom scores on days when the pollen count was greater than 10 grains/m3 revealed 256 μg/day of budesonide therapy to be significantly more effective in reducing combined symptom scores as well as the individual scores for sneezing and runny nose, compared with 200 μg/day fluticasone propionate. The higher dose of budesonide (256 μg/day) was also more effective than the lower dose (128 μg/day) in reducing sneezing scores and statistical significance was almost reached for the reduction in combined symptom and runny nose scores. Substantial or total control of symptoms was achieved by 31.4%, 85.3%, 88.4%, and 81.9% of patients receiving placebo, 128 μg/day of budesonide, 256 μg/day of budesonide, and 200 μg/day of fluticasone propionate, respectively. The incidence of adverse events was low in all treatment groups. In conclusion, both budesonide and fluticasone propionate treatments were effective and well-tolerated in the treatment of seasonal allergic rhinitis. However, 256 μg/day of budesonide tended to be more effective than 200 μg/day of fluticasone propionate and 128 μg/day of budesonide, especially when patients were exposed to a higher pollen load.

The effect of immunotherapy on the serum levels of eosinophil cationic protein in seasonal allergic rhinitis

1997 ◽  
Vol 22 (2) ◽  
pp. 100-105 ◽  
Author(s):  
Y. OHASHI ◽  
Y. NAKAI ◽  
Y. KAKINOKI ◽  
Y. OHNO ◽  
H. OKAMOTO ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Eosinophil Cationic Protein ◽  
Serum Levels ◽  
Cationic Protein

scholarly journals Comparative efficacy of different antihistamines II generation in adult patients with seasonal allergic rhinitis

2017 ◽  
Vol 19 (3) ◽  
pp. 101-108 ◽  
Author(s):  
O.S. Bodnya ◽  
◽  
N.M. Nenasheva ◽  
G.V. Andrenova ◽  
D.O. Sinyavkin ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Adult Patients ◽  
Comparative Efficacy

scholarly journals Optimization of allergen-specific immunotherapy in patients with seasonal allergic rhinitis and secondary immunodeficiency syndrome

2019 ◽  
pp. 66-71
Author(s):  
L. P. Sizyakina ◽  
E. N. Zabrodskaya ◽  
I. A. Andreeva
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Standard Therapy ◽  
Specific Immunotherapy ◽  
Immune Deficiency Syndrome ◽  
Allergic Diseases ◽  
Deficiency Syndrome ◽  
Preventive Therapy ◽  
Allergen Specific Immunotherapy ◽  
Low Efficiency

Seasonal allergic rhinitis (SAR) remains an important medical and social problem, the importance of which is determined by the steady growth of morbidity, the expansion of the spectrum of pollen sensitisation, the development of complications in the form of otitis, sinusitis, eustachitis, and often low efficiency of standard therapy. One of the reasons for the complication of allergic diseases in general and SAR in particular is the combination of allergy and secondary immune deficiency syndrome (SID). In order to form an understanding of the possibilities of allergen-specific immunotherapy (ASIT) optimization, an analysis of the clinical, immunological and allergic status of patients suffering from SAR with concomitant SID syndrome who received two ASIT courses. All patients (40 people aged 18-60 years) were divided into two groups: those receiving only SIT (20 people) and those receiving gamma-D-glutamyl triptofan (GDGT) immunomodulator treatment (20 people) in addition to standard therapy. The results of the study clearly indicate a sufficiently high therapeutic efficacy of the used approach of combination of preventive immunocorrection and ASIT, which consists in a reliable reduction of morbidity and duration of ARVI episodes, more significant effectiveness of ASIT. The basis of the positive effect of preventive therapy of GDGT is the restoration of functional parameters of the immune system.

Sign in / Sign up

Export Citation Format

Share Document